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The mammalian orthoreovirus Type 3 Dearing has great potential as oncolytic agent in cancer therapy. 
One of the bottlenecks that hampers its antitumour efficacy in vivo is the limited tumour-cell infection 
and intratumoural distribution. This necessitates strategies to improve tumour penetration. In this 
study we employ the baculovirus Autographa californica multiple nucleopolyhedrovirus as a tool to 
expand the reovirus’ tropism and to improve its spread in three-dimensional tumour-cell spheroids. 
We generated a recombinant baculovirus expressing the cellular receptor for reovirus, the Junction 
Adhesion Molecule-A, on its envelope. Combining these Junction Adhesion Molecule-A-expressing 
baculoviruses with reovirus particles leads to the formation of biviral complexes. Exposure of the 
reovirus-resistant glioblastoma cell line U-118 MG to the baculovirus-reovirus complexes results in 
efficient reovirus infection, high reovirus yields, and significant reovirus-induced cytopathic effects. As 
compared to the reovirus-only incubations, the biviral complexes demonstrated improved penetration 
and increased cell killing of three-dimensional U-118 MG tumour spheroids. Our data demonstrate 
that reovirus can be delivered with increased efficiency into two- and three-dimensional tumour-cell 
cultures via coupling the reovirus particles to baculovirus. The identification of baculovirus’ capacity to 
penetrate into tumour tissue opens novel opportunities to improve cancer therapy by improved delivery 
of oncolytic viruses into tumours.
The wild-type mammalian orthoreovirus (RV) type 3 Dearing (T3D) is under investigation as oncolytic agent in 
pre-clinical research and phase I, II and III clinical trials1. The RV species belongs to the genus Ortheoreovirus 
within the family of Reoviridae, characterized by a segmented dsRNA genome packaged into a double-layered 
icosahedral-shaped protein capsid. The canonical cellular receptor for reovirus is Junction Adhesion Molecule-A 
(JAM-A)2. JAM-A is a type I transmembrane protein with two extracellular immunoglobulin domains and a 
short cytoplasmic tail. The protein is concentrated at the apical region of intercellular tight junctions of epithelial 
and endothelial cells3. After sialic acids-mediated attachment of RV to the host cell, the RV’s spike protein σ1 
engages JAM-A to establish a high-affinity interaction.
The mechanism of RV T3D oncolysis can be primarily attributed to its unrestricted replication and killing 
of tumour cells bearing genomic mutations that lead to active RAS signalling via RalGEF/p38 downstream 
pathways, while in untransformed, healthy cells the reovirus’ infectious cycle is limited by the dsRNA-activated 
protein kinase R (PKR)-mediated antiviral responses4,5. Additionally, other cellular determinants as receptor 
availability and virus uncoating efficiency have been shown to influence RV’s ability to kill cancer cells6–10.
The reovirus-induced tumour eradication in vivo is a result of both the direct cytolytic effect of the virus and 
indirect tumour killing in response to viral-induced innate and adaptive immune responses. Replication of the 
oncolytic-virus increases anti-tumour immunity, thereby enhancing the therapeutic efficacy of RV11,12.
To date more than 30 clinical trials exploiting RV for tumour treatment are ongoing or have been completed1. 
RV demonstrates an outstanding safety profile and anti-tumour efficacy has been witnessed in several cancer 
types. In these studies RV is used either as monotherapy or in combination with conventional treatment13. 
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Although safe, many patients show partial and transient responses to the treatment, making further improvement 
of RV-based cancer treatment necessary11,12.
Several hurdles that hamper antitumour efficacy have been defined. Systemic delivery can be thwarted by, 
for instance, circulating antibodies against RV, activation of the innate immune system by pathogen-associated 
molecular patterns (PAMPS) on the virus, and high interstitial fluid pressure which hampers the extravasation 
of the virus14,15. Even if substantial amounts of virus particles enter the tumour after intratumoural adminis-
tration, clearance of the entire tumour is still not ensured12,16. Physical barriers posed by the stromal compart-
ment, including the extracellular matrix, as well as antiviral immunity may limit the distribution of the virus14,15. 
Moreover, RV’s ability to enter tumour cells may be negatively affected by the scarcity and inaccessibility of its 
cellular receptor JAM-A, although it remains to be established how important this factor is, taking into account 
the existence of alternative, e.g. JAM-A-independent, entry mechanisms17,18.
In our efforts to identify strategies that can improve RV’s applicability and oncolytic potency, we selected 
baculovirus (BV) as a potential ally. BVs are insect viruses with a very narrow host range. BVs exhibit in two 
distinct phenotypes during their natural infection cycle, the occlusion-derived viruses (ODV) that mediate the 
horizontal transmission between insect hosts and the budded viruses which are produced by the host’s midgut 
epithelial cells, and establish systemic infection inside the insect. The formation of ODV critically relies on the 
viral capacity to produce the polyhedrin protein. In biotechnology application, polyhedrin deletion mutants are 
employed that can only form the rod-shaped, membrane-enveloped budded BVs. These BVs gained their popu-
larity in production platforms for recombinant protein production and as gene-delivery vehicles19. BV’s circular 
double-stranded DNA genome (134kbp) is relatively easy to engineer and can harbour large transgenes. BV can 
be modified for the efficient expression of heterologous transgenes in a broad panel of mammalian, bird, and fish 
cells, however the virus is unable to replicate in these species. Considering this inability to replicate in mammals 
and the fact that it is not pathogenic to humans, BV is regarded as fairly safe to use in human cells19, and as a safe 
replication-defective gene-transfer vector for use in humans20. The most commonly used BV is the Autographa 
californica multiple nucleopolyhedrovirus (AcMNPV), isolated from an alfalfa looper in the early 1970s21.
It has been shown that the cellular receptor for a large number of Adenovirus (AdV) species, the Coxackievirus 
and Adenovirus receptor (CAR) can be expressed on the baculovirus AcMNPV envelope, creating BVCAR virions. 
This enabled AdV particles to bind to the baculovirus AcMNPV envelope, forming BVCAR-AdV complexes22. 
Cells that were resistant to HAdV-5 vectors carrying a green fluorescent protein (GFP) reporter (AdV.GFP) 
turned GFP positive upon administration of the BVCAR-AdV.GFP complexes. This demonstrates that the AdV 
was able to enter cells by piggybacking on the recombinant BVCAR virus. Additionally, in a separate study it was 
demonstrated that BV, harbouring the EGFP gene under control of the human cytomegalovirus (hCMV) imme-
diate early promoter, was able to penetrate through several cell layers into tumour-cell spheroids and into prostate 
cancer xenografts in a murine model23.
Together, this prompted us to study the concept of enhancing RV’s cell entry and tissue penetration capac-
ity by piggybacking on BV virions. Therefore we expressed RV’s cellular receptor JAM-A onto the BV enve-
lope, allowed RV to bind to the BVJAM viruses, and tested the resulting BVJAM-RV complex for reovirus 
infection of JAM-A-deficient U-118MG glioma cells in two-dimensional standard cell-culture conditions and on 
three-dimensional tumour-cell spheroid cultures. We show that the BVJAM-RV complexes facilitate infection and 
replication of RV and increase cell killing in U-118 MG glioblastoma cells which are refractory to RV under nor-
mal cell culture conditions17. Moreover, RV achieved deeper penetration and spread into spheroids, and increased 
spheroid cell killing upon administration of RV complexed with BVJAM.
Results
Expression of JAM-A on the baculovirus AcMNPV envelope. To generate a BV vector that carries 
the RV receptor JAM-A on its envelope, a recombinant BV was engineered that carries the human JAM-A cDNA 
under control of the BV polyhedrin promoter. The full-length JAM-A gene including a human influenza hemag-
glutinin (HA) tag was inserted in the pBlueBac4.5/V5-His vector. After generation, production and purification 
of the recombinant baculovirus BVJAM, expression of the JAM-A protein on the BVJAM envelope was confirmed by 
Western blot analysis using an α-HA antibody on the lysate of BVJAM infected Sf9 cells (Fig. 1a). The double band 
around 42 kDa is probably due to incomplete N-linked glycosylation of the JAM-A protein at position 185 in Sf9 
cells24. While baculovirus-insect cells are capable of N-linked glycosylation of proteins, the glycosylation in these 
cells is incomplete compared to mammalian cells25.
Subsequently, we examined the BVJAM virions by immune-electron microscopy (EM). Virions were applied 
to an EM grid and incubated with α-JAM-A antibodies ab17261 or sc-53623, followed by a 10-nm colloidal 
gold-tagged secondary antibody and analysed by EM microscopy (Fig. 1b–d). Low background labelling is 
observed for both antibodies (Fig. 1b). Most BVJAM virions observed held one (Fig. 1c), or more gold grains per 
virion (Fig. 1d). Although the number of gold grains attached to a BV does not necessarily correlate to the num-
ber of JAM-A molecules on the envelope, it can be concluded that JAM-A was efficiently expressed at the surface 
of BVJAM virions.
BVJAM formed a complex with RV and facilitated infection of RV in U-118 MG cells. To inves-
tigate whether RV was capable of binding to BVJAM to form a BVJAM-RV virus complex, we analysed the bivi-
ral complex by EM (Fig. 2a). Mostly binary complexes were observed where one RV was bound to one BVJAM 
(Fig. 2b) or more RV were found to associate with a BVJAM virion (Fig. 2c). To examine whether the formation 
of the BVJAM-RV complexes was dependent on the presence of JAM-A in the BV capsid we performed an anti-
body blockage experiment on the JAM-A negative glioblastoma cell line U-118 MG. Under standard cell culture 
conditions these glioma cells are resistant to RV as infection strictly depends on expression of JAM-A on the 
cell surface26. First, two different α-JAM-A antibodies, ab17261 and sc-53623, were tested for their capacity to 
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recognize JAM-A on the JAM-A-positive cell line HER911 by flow cytometry. JAM-A-negative U-118 MG cells 
served as negative control. Both ab17261 and sc-53623 α-JAM-A antibodies were able to bind to JAM-A on the 
surface of HER911 cells, whilst the signal for both antibodies on U-118 MG cells did not exceed background level 
(Fig. 2d). Subsequently, both antibodies were examined for their ability to inhibit RV infection on RV-permissive 
HER911 cells. Cells were incubated with α-JAM-A antibodies or with unrelated control, antibodies of the same 
provider, followed by infection with RV. Two days post-infection, cells and medium were harvested and the RV 
yield was determined by plaque assays on HER911 cells. The α-JAM-A antibody ab17261 did not impede RV 
infection in HER911 cells as the virus yield was similar to the control samples that were not exposed to antibodies 
or pre-incubated with unrelated antibody controls. In contrast, HER911 cells incubated with α-JAM-A antibody 
sc-53623 prior to RV infection exhibited a ten-fold decrease in RV infectious titer compared to the control sam-
ples (Fig. 2e). This demonstrated that infection of HER911 by RV is dependent on the availability of JAM-A on 
the surface and that the RV infection could be inhibited by blocking the receptor with antibody sc-53623. Hence, 
the α-JAM-A antibody sc-53623 was used in the confirmatory antibody blockage experiment on U-118 MG cells.
In this experiment BVJAM particles were exposed to α-JAM-A antibody sc-53623, unrelated control antibodies 
of the same provider or no antibodies prior to incubation with RV. Subsequently, this mixture was administered 
to U-118MG cells. Cells exposed to RV alone or RV incubated with BV-GFP (lacking JAM-A), without anti-
body pre-incubation, were used as controls. Two days post-infection, cells and medium were harvested and the 
Figure 1. RV’s cellular receptor JAM-A is present on the BV envelope. (a) Western blot analysis of Sf9 cells 
infected with BVJAM. The blot was reacted with mAb α-HA followed by antibody-alkaline phosphatase, to detect 
the presence of JAM-A in infected cells. (b–d) Electron microscopic images of BVJAM, negatively stained using 
uranyl acetate and incubated with mouse mAb α-JAM-A (i = sc-53623, ii = ab17261) followed by α-mouse 
antibody tagged with 10-nm colloidal gold. (b) Example of a BVJAM field on grid showing low background 
labelling. (c,d) Enlargements of BVJAM virions bearing respectively a single (c) or multiple (d) gold grains.
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Figure 2. RV and BVJAM associate and form a biviral complex. (a) Schematic representation of the BVJAM-RV 
complex. RV attachment protein σ1 bound to JAM-A expressed on the BV envelope. (b,c) Electron microscopy 
images of BVJAM-RV complexes. The virions were negatively stained with uranyl acetate. Most complexes 
consisted of one BVJAM and one RV virion (b), some complexes showed other combinations of single or multiple 
BVJAM and RV virions (c). (d) Flow cytometry analyses of recognition of JAM-A on HER911 cells and U-118MG 
cells as negative control, by α-JAM-A antibodies ab17261 and sc-53623. (e) The RV yields from HER911 cells 
and culture medium upon incubation with α-JAM-A antibodies ab17261 and sc-53623 or as controls unrelated 
antibodies of the same provider as controls. The error bars represent the standard deviation (n = 3), p values: 
** ≤ 3E-4 (f) The RV yields from U-118 MG cells and culture medium after incubation with BVJAM or BVJAM 
exposed to α-JAM-A antibodies sc-53623 or unrelated control antibodies of the same provider. The dashed line 
represents RV input. The error bars represent the standard deviation (n = 3), p values: * ≤ 4.4E-2, ** ≤ 8.8E-3.
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infectious RV titer was determined by plaque assays on HER911 cells. While the RV yield on U-118 MG cells in 
the control conditions did not exceed the input level, the RV yield in cells exposed to RV incubated with BVJAM 
was 100-fold higher (Fig. 2f). This increase in RV yield was completely abolished upon exposure of U-118 MG 
cells to RV which was incubated with BVJAM pre-exposed to α-JAM-A antibodies, while pre-incubation of BVJAM 
with unrelated control antibodies prior to RV addition did not have an effect on the RV yield. Additionally, the 
RV yield was fully preserved upon addition of α-JAM-A antibodies after incubation of BVJAM with RV (data not 
shown). These results provided evidence that RV was able to bind to BVJAM and formed a virus complex. These 
complexes facilitated RV infection in U-118 MG cells that otherwise resist wild-type RV infection.
To further study the BVJAM-mediated RV infection we assessed the fraction of RV-infected U-118 MG cells 
upon exposure to BVJAM-RV by flow cytometry. Various ratios of viral particles (vp) of RV and BVJAM were com-
plexed prior to addition to U-118 MG cells. The cell population was harvested at 40 h post-incubation, fixed and 
stained for the presence of RV capsid protein σ3. Upon administration of RV alone, 1% of the cells became RV 
positive at the highest dose of 5000 vp per cell (Fig. 3a). Exposure of U-118MG cells to BVJAM-RV in different 
ratios (50–5,000 vp RV per cell and 0–10,000 vp BV per cell) increased notably the percentage of RV infected cells 
up to 75%. Presumably, the actual percentage of infected cells was even higher at the highest virus concentrations 
applied (5,000 vp RV and 10,000 vp BV per cell) as the majority of cells already succumbed to the virus infection 
and only 2,500 cells could be measured by the flow cytometer (compared to 10,000 cells for the other conditions). 
Furthermore, it was apparent that the concerted increase of RV and BVJAM particles led to an increase in the per-
centage of RV-infected cells.
To assess the productive replication of RV in U-118MG cells upon infection with BVJAM-RV or with RV alone, 
the RV infectious yields from the cells were analysed four days post-infection. The addition of BVJAM had the 
most substantial effect on the RV yield at low concentrations of RV; at 5 and 50 vp RV per cell the addition of 
BVJAM increased the yield more than 10,000- and 1,000- fold, respectively (Fig. 3b). At higher RV concentrations 
(500 and 5,000 vp per cell), the yield increase was respectively fifteen- and four-fold upon incubation with BVJAM. 
Notably, at these higher RV concentrations the difference in yield between applying 1,000 or 10,000 BVJAM par-
ticles per cell was relatively minor. However, at lower RV concentrations the increase was stronger, presumably 
because progeny RV virions produced by the U-118 MG cells could engage with residual free BVJAM particles, 
thereby allowing the progeny viruses to productively infect uninfected cells.
Cell viability of U-118 MG cells was decreased via apoptosis after RV infection supported by 
BVJAM. The BVJAM-RV complex facilitates infection and replication of RV in U-118 MG cells. Subsequently, 
U-118 MG cells were used to evaluate cytolytic activity of RV upon administration with BVJAM at five days 
post-infection by a cell viability assay (Fig. 4a). Administration of BVJAM without RV did not significantly affect 
Figure 3. Complexing BVJAM and RV increases RV infection of U118-MG cells. (a) Flow cytometry analyses 
of the fraction of RV infected U-118 MG cells, stained for RV capsid protein σ3, upon incubation with either 
RV or with different ratios of BVJAM-RV complexes 40 h post-infection. The error bars represent the standard 
deviation (n = 2). (b) RV yields from U-118 MG cells upon infection with either RV or with different ratios of 
BVJAM-RV complexes as determined by plaque assays. The error bars represent the standard deviation (n = 3), 
for BVJAM-RV ratios 0:5 and 1,000:5 (n = 2).
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cells viability, even at the highest concentration of BVJAM (10,000 vp per cell) (p = 0.17). Also the infection of 
U-118 MG with RV alone, in concentrations ranging from 0 to 5,000 vp per cell, did not reduce cell viability 
compared to the control cells (p = 0.30 at 5,000 vp per cell). In contrast, exposure of the cells to the BVJAM-RV 
complex caused substantial cell killing in U-118 MG cells. At a BVJAM-RV ratio of 10,000 – 5 vp per cell a signifi-
cant decrease in cell viability compared to the RV only condition could be observed. Both the increase of RV and 
of BVJAM particles decreased U-118 MG cell viability. As BV is not able to replicate in mammalian cells and is not 
cytolytic, this decrease in viability can be attributed to RV-mediated cell killing.
Next, we studied whether the BV-mediated RV infection induced cell killing via apoptosis. Therefore the enzy-
matic activity of two key effectors in the apoptotic pathway, caspase-3 and -7, was measured in the lysate of U-118 
MG cells at four days post-infection. Administration of BVJAM or RV only did not lead to induction of apopto-
sis in the cells (Fig. 4b). However, incubation of cells with biviral BVJAM-RV increased activity of caspase-3/7, 
demonstrating an advanced stage of apoptosis in the infected cells. Taken together, our data showed improved 
RV-mediated infection and cell killing of two-dimensional U118MG cultures after co-incubation of RV with 
BVJAM.
Enhanced RV penetration and cell killing of U-118 MG spheroids upon administration in 
complex with BVJAM. To explore whether the BVJAM-RV complexes can stimulate RV transduction in 
three-dimensional spheroid cultures of U118 MG cells, the penetration depths of RV into spheroids, upon admin-
istration with BVJAM, were evaluated as a surrogate for the RV infection and penetration potency.
To compare the penetration depths of the vectors, it is essential to identify the spheroid’s midpoints. Hence, 
the spheroids were fixed after harvesting, sliced into sections and the diameter of each section was measured. 
These values were graphically plotted and a trend line was set to pinpoint the section with the largest diameter, 
representing the middle section of the spheroid. See Fig. 5a for an illustration of this procedure.
To evaluate the penetration depth of RV alone (10,000 vp per cell) or in combination with BVJAM (ratio 
RV:BVJAM = 1:2.5) over time, the spheroids (25,000 cells at start) were harvested at two, four and six days 
post-infection. In the middle sections the extent of reovirus infection was visualized by staining for the presence 
of RV capsid protein σ3. As described previously, RV as a single agent is able to infect spheroids composed of 
U-118 MG cells whilst U-118 MG monolayer cultures are resistant to infection with RV. This effect was attributed 
to factors that are secreted by the spheroids, such as cathepsin B and L17. It is therefore not surprising to observe 
that RV as single agent caused infection in U-118 MG spheroids (Fig. 5b). However, when BVJAM-RV complexes 
were applied, this resulted in an increased infection of cells in the outer rim of the spheroids, observed just 
after two days. Moreover, there were RV infected cells deeper in the spheroid showing that RV had penetrated 
deeper into the spheroid in combination with BVJAM. This effect was even more pronounced at four and six days 
Figure 4. Enhanced RV-mediated killing of U-118 MG cells by apoptosis upon infection with BVJAM-RV. (a) 
Analyses of the cell viability of U-118 MG cells by WST-1 assay at four days post-infection with BVJAM, RV, 
or BVJAM-RV complexes. Uninfected cells were set at 100% viability. The error bars represent the standard 
deviation (n = 9), p values: * = 3.9E-2, ** = 4.8E-3, *** < 1E-4. (b) Caspase-3 and -7 analysis in the lysate of 
U-118 MG cells upon infection with BVJAM, RV or BVJAM-RV complexes. Measurements were normalized to 
the caspase-3 and -7 values in uninfected cells. The error bars represent the standard deviation (n = 3), p values: 
** ≤ 2.1E-3, *** < 1E-4.
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post-infection. In spheroids incubated with BVJAM-RV the RV-infected cells were present throughout the entire 
spheroid at six days post-infection and reached the centre of the spheroid, whereas incubation with RV only 
led to infection of the outer rim. Note that the spheroids exposed to RV and BVJAM-RV became smaller over 
time as compared to uninfected spheroids, which was caused by detachment of dead cells from the spheroids. 
Quantification of the difference in penetration of RV administered alone or in complex with BVJAM was accom-
plished by measuring the uninfected (unstained) centre area of the spheroid. From Fig. 5c it becomes apparent 
that at six days post-infection the uninfected area of spheroids slices infected with RV alone was twice the size 
of the uninfected area of spheroids slices infected with the BVJAM-RV complex. In a subsequent experiment, the 
effect of increasing RV amounts (2.7–2,700 vp per cell) with a surplus of BVJAM particles (30,000 vp per cell) onto 
spheroids was evaluated at six days post-infection. Although infection with RV alone could not be detected at 
2.7 vp per cell, the spheroids stained positive for RV from 27 vp per cell onwards (Fig. 5d). However, the virus 
could only be detected in the outer rim of the spheroid and did not reach the spheroid centre, even at the highest 
concentration of 2,700 vp per cell. If administered with a surplus of BVJAM particles, the spheroids showed patches 
σ3 positive cells evidencing RV infection already at 2.7 vp per cell. With increasing RV concentrations, infections 
Figure 5. Improved penetration and spread of RV in U-118 MG spheroids upon infection with BVJAM-RV. 
(a) Example of a graph assigning the midpoint of a spheroid. After the spheroids (25,000 cells at start) were 
fixed and sectioned, the diameter of each of the spheroid sections was measured. These values were combined 
in a graph as represented here and the trend line through the data points was used to determine the spheroid 
section with the largest diameter. (b) Representative images of RV penetration analysis in U-118 MG spheroids, 
either as single agent (10,000 vp/cell) or in combination with BVJAM in a RV:BVJAM ratio of 1:2.5. Two, four 
and six days post-infection spheroids were fixed, sliced and stained for the presence of RV capsid protein σ3 
by immunocytochemistry. (c) Uninfected area of spheroids infected as in (b) with RV only or the BVJAM-RV 
complex at six days post-infection. For each spheroid the uninfected area of three to five middle sections was 
measured and averaged. The error bars represent the standard deviation (n = 4 spheroids), p value: ** = 9.2E-3. 
(d) Representative images of RV titration experiment on spheroids infected with RV only or in the presence of a 
surplus of BVJAM at six days post-infection through immunocytochemistry staining for RV capsid protein σ3.
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extended deeper into the spheroid and at 270 and 2,700 RV vp per cell σ3 staining was evident in the centre of 
the spheroids. Together, these data showed that BVJAM facilitated RV penetration and spread throughout the 
spheroids.
Furthermore, we assessed whether administration of the BVJAM-RV complex led to increased cell death in 
spheroid cultures compared to RV used as single agent. To this end, the viability of spheroids of 25,000 cells (25 K) 
and 5,000 cells (5 K) was analysed at six days post-infection. Incubation of spheroids with RV only, BVJAM only or 
RV combined with BV-GFP served as controls. Both 25 K and 5 K spheroids that were exposed to BVJAM showed a 
slight decrease in viability (Fig. 6a,b). However, this effect did not correlate to the BVJAM dose applied. The highest 
concentration of RV (5,000 vp per cell) reduced the viability of the spheroids of both sizes considerably (to around 
60%). A similar reduction in viability was obtained upon exposure of spheroids to RV plus BV-GFP. As these 
viruses were not able to form a complex, this showed that solely the presence of BV particles in a sample with RV 
was not sufficient to cause an additional decrease in viability of the spheroids. In contrast, incubation of the sphe-
roids with the BVJAM-RV complex resulted in a significant decrease in cell viability compared to application of RV 
only. This decrease was most pronounced in spheroids of 5,000 cells. At ratio 500 RV–1,500 BVJAM vp per per cell 
we observed a 20% increase in cell killing as compared with the RV only condition for the 25 K spheroids and a 
33% increase in the 5 K spheroids and for 5000 RV–15,000 BVJAM vp per cell this increase in cell death was respec-
tively 22% versus 47%. Together these results demonstrate that RV in complex with BVJAM penetrated deeper into 
the spheroids and caused more tumour cell death than RV only under these conditions.
Discussion
In a previous study, Granio et al. elegantly provided proof-of-concept of binding adenovirus particles on 
CAR-exposing BV, to increase the transduction of cell lines that are normally refractory to AdV infection22. Here 
we show for the first time that RV complexed to its receptor JAM-A expressed on the BV envelope transduces and 
kills the RV-resistant U-118 MG glioma. In spheroid cultures BVJAM facilitated the RV to penetrate deeper into 
the three-dimensional U-118 MG cell mass, causing increased cell killing.
An effective oncolytic virotherapy must overcome the various hurdles that hamper therapeutic efficacy. A 
strong initial infection and rapid spread of the therapeutic virus can enhance anticancer efficacy15,27. As became 
apparent from our studies in three-dimensional tumour spheroids, BV assisted RV in two interrelated aspects; 
Figure 6. Improved cell killing of U-118 MG spheroids upon infection with BVJAM-RV. Spheroids of 25,000 (a) 
or 5,000 (b) cells at start were either mock treated or transduced with BVJAM only, RV only or RV pre-incubated 
with BVJAM or BV-GFP. At six days post-infection the viability of the spheroids was assessed by WST-1 assay. 
Mock-treated cells were set at 100% viability. The error bars represent the standard deviation (n = 8), p values: 
* = 3.1E-2, ** = 1.6E-2, *** = 2E-4.
www.nature.com/scientificreports/
9SCieNTifiC REPORTS | 7: 17654  | DOI:10.1038/s41598-017-17709-z
(i) more cells became RV positive, already observed early after infection and (ii) RV penetrated deeper into the 
spheroids.
The increased cell killing together with improved spreading/penetration could potentially contribute to 
more effective immunogenic lysis of the infected cells buried inside a tumour, allowing more and additional 
tumour-associated antigens to be released. These neoantigens could enhance tumour-antigen processing and 
presentation by professional antigen presenting cells, eventually culminating in a more potent immune response 
against the tumour cells12,28.
BVJAM viruses were produced in Sf9 cells after infection with recombinant BV expressing JAM-A under the 
control of the polyhedrin promoter. We demonstrated expression of the JAM-A protein on the BV envelope 
by EM analysis. The majority of JAM-A positive BVs showed only few immunogold grains per virion. Also, 
predominantly single RVs were shown bound to BVJAM virions. These findings mimic the EM data shown by 
Granio et al. in their study on BVCAR-AdV complexes. These authors compared expression of CAR- and BV 
membrane protein GP64, which showed similar numbers of gold grains and, similarly to our results, mostly single 
CAR-staining gold particles per virion. As GP64 is an intrinsic BV protein, this illustrated that the immunogold 
labelling of the acquired CAR protein was equally potent. Although RV and AdV originate from distinct virus 
families, with a different genetic background and limited similarities in their infectious mechanism, both viruses 
show a similar mechanism of attachment to host cells. Both JAM and CAR are glycoproteins belonging to the 
immunoglobulin superfamily and form homodimers with structural similarities which are expressed at regions 
of cell-cell contact29. Moreover, the trimeric attachment proteins of RV and AdV, σ-1 and fiber, have comparable 
structural regions and are able to interact with their receptors in a similar manner through high affinity binding 
(dissociation constant, KD, of 0.9–2.4 nM for RV2,30 and 2–6 nM for AdV31,32)33,34. It is therefore conceivable that 
the JAM-A expression on the BV envelope and the binding kinetics of BVJAM-RV reflected the situation of CAR 
expression of BV and the binding of AdV to BVCAR.
The mechanism of BV entry into mammalian cells has been thoroughly studied and is mediated by the BV 
GP64 major envelope fusion protein. This trimeric glycoprotein, which is found polarized on the end of the BV 
where both budding and cell entrance initiates, is responsible for the attachment to the mammalian host cell 
and the subsequent process of virus internalization35,36. In this study we showed that, in contrast to RV only, the 
BVJAM-RV complex was able to establish a productive RV infection in U-118 MG cells, indicating that the capacity 
of the BV GP64 protein to attach to and enter the U-118 MG cell was not obstructed by the RV cargo.
It remains to be clarified how BVJAM-RV complexes internalize into the JAM-A deficient U-118 MG cells. 
Separately, both RV and BV are thought to enter mammalian cells via clathrin-mediated endocytosis37,38, although 
for both viruses also other endocytic pathways are suggested in the cellular uptake process18,35. Considering that 
the size of the BVJAM-RV complex exceeds the 200 nm size limit for the diameter of clathrin-dependent endocytic 
vesicles, it could not be excluded that the internalization of biviral complexes occurred via macropinocytosis- or 
phagocytosis-mediated endocytosis. An EM study using cell transduction by baculovirus-human adenovirus 
complexes (BVCAR-AdV22) has shown that the attachment of BV to the cell surface induces the formation of 
clathrin-coated vesicles. However, at later times of the viral entry process, EM analysis also showed BVCAR and 
HAdV5 particles in large intracytoplasmic vesicles of which size and morphology corresponds to macropinocytic 
or phagocytic vesicles22.
Together, these results suggested that, similar to the BVCAR-AdV complexes, the cell internalization of the 
BVJAM-RV complex can result from two co-existing mechanisms, clathrin-dependent and clathrin-independent 
endocytosis. This hypothesis is supported by many observations that a given virus can infect cells via different 
endocytic pathways, as described above for RV and BV18,33 as is, for example, shown for human adenovirus which 
can use both clathrin-mediated uptake and macropinocytosis39–41. Inside the endocytic compartment, RV is sub-
ject to conformational transformations, characterized by the loss of several capsid proteins including attachment 
protein σ142. At this stage in the infection cycle we expected RV to lose the connection with BVJAM and migrate 
to the cytoplasm alone. This is in agreement with the results obtained by Granio et al., illustrating by EM that the 
BVCAR-AdV complex is internalized as a whole and did not separate until they were in a cytoplasmic vesicle from 
which AdV escaped separate from BVCAR22.
Although investigating the mechanism by which BV is able to penetrate deep into tumour spheroids is beyond 
the scope of this study, we scrutinized the literature for potential clues.
In the natural infection cycle of BV AcMNPVs, progeny BV viruses escape the midgut epithelial cells on the 
basal side. From there, two main routes of systemic virus spread have been proposed: (i) the virus directly pene-
trates the basal lamina secreted by midgut cells to reach the underlying tracheal branches (the respiratory system 
of the insect). (ii) the tracheal cells reach into the basal lamina of the midgut cells and the virus would need to 
penetrate the basal laminae secreted by the tracheal cells to establish systemic spread43–45. In either theory, the 
virus would need to cross a basal lamina. Basal laminae or basement membranes are a specialized type of extra-
cellular matrix (ECM) present in both invertebrates and vertebrates and consist of flexible sheets, build up from 
different proteins (e.g. collagen type IV, laminin and fibronectin), that form a more compact and dense matrix 
network than other types of ECM46,47.
Although the precise process by which BV penetrates the basal lamina of the tracheal cells is not fully eluci-
dated, several studies point to a crucial role for the BV-encoded viral fibroblast growth factor (vFGF). BVs are 
the only viruses that produce FGF. The vFGF is made early in BV-infected insect cells and is shuttled to the cell 
surface where it anchors to heparin sulphate proteoglycans. Upon budding from the cell, the virus attaches vFGF 
to the cell-membrane derived envelope48,49. It has been shown that vFGF accelerates virus spread and diminishes 
the time required to kill the insect by initiating a cascade of events (involving matrix metalloproteases and effector 
caspases) leading to remodelling of the basal lamina, thereby allowing BV to penetrate this layer and infect the 
underlying tracheal cells43,48,49.
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In oncolytic virotherapy, the ECM in and around the tumour mass can hamper the spread of the viruses15 and 
we already showed the abundance of ECM in U-118 MG spheroids in a previous study17. Therefore we envision 
a function for the membrane-anchored vFGF in assisting BV to penetrate the ECM surrounding U-118 MG 
tumour cells and RV, being coupled to BVJAM, might take advantage of this mechanism.
The findings that BV is able to spread through tissue and can deliver cargo with therapeutic value are very 
promising. On the one hand, it would be worthwhile to investigate the mechanism controlling the spreading 
capacity of BV in a human tumour environment as this instrument may be translated to other oncolytic virus- 
and gene therapy systems. On the other hand, BV vectors themselves hold great potential for use as gene ther-
apy vectors, not exclusively as a result of their capacity to transduce cells and penetrate tissues, as described 
in this study and by others23,50, but also because it is relatively easy to genetically engineer BVs, for instance to 
incorporate therapeutic transgenes. The BV-insect cell expression system is already used extensively to produce 
products for clinical use and considerable pre-clinical efforts are being made on the use of BV for gene therapy 
purposes19,27,50–52. Although still in its infancy, it is plausible that BV vectors will find their way towards patient 
application53. Our findings could be of great significance for such developments.
Taken together, in this study we showed that RV in the BVJAM-RV complexes is able to transduce and kill the 
RV-resistant U-118 MG glioma cells in standard cell culture conditions and showed an enhanced penetration and 
cell killing capacity in U-118 MG tumour cell spheroid cultures. These results are auspicious, both conceptually, 
as they demonstrate that there are mechanisms to boost the intratumoural spread of oncolytic viruses, and for 
their therapeutic implications, as BV’s benefits as a gene therapy vector may be implemented clinically in the 
future.
Material and Methods
Cell lines. The human cell lines U-118 MG (glioblastoma) and HER911 (HAdV-C5 early region 1 transformed 
human embryonic retinoblasts)54 were maintained at 37 °C in a humidified atmosphere of 5% CO2, in high-glu-
cose Dulbecco’s modified Eagle’s medium (DMEM, Gibco | Thermo Fisher Scientific, Waltham, MA, USA) sup-
plemented with 8% foetal bovine serum (FBS) (Gibco | Thermo Fisher Scientific) and penicillin-streptomycin 
(pen-strep) (Gibco | Thermo Fisher Scientific).
The insect cell line Spodoptera frugiperda Sf9 was cultured as monolayer in Sf-900 II Serum Free Medium 
(Gibco | Thermo Fisher Scientific), supplemented with 5% FBS and pen-strep. Routinely, cells were passaged in 
two-third of new medium and one-third of conditioned medium and placed at 27 °C in a humidified atmosphere 
without addition of CO2.
Virus production and purification. Reovirus. The wild-type orthoreovirus T3D strain R124 (here 
referred to as reovirus (RV)) was isolated earlier from a stock of reovirus T3D by two rounds of plaque purifi-
cation using HER911 cells26. RV propagation was performed as described before17. In brief, HER911 cells were 
infected with a multiplicity of infection (MOI) of 1 to 3 plaque forming units (PFU911) per cell and the medium 
was replaced at three h post-infection. Cells and medium were harvested at 72 h post-infection and separated by 
centrifugation (10 min at 3000 g). The cell fraction was resuspended in a small volume of medium and subjected 
to three cycles of freezing and thawing. After centrifugation, the supernatant was mixed with the medium frac-
tion and subsequently purified by a double discontinuous caesium chloride (CsCl) gradient centrifugation. The 
virus was isolated from the gradient with a syringe and desalted in an Amicon Ultra-15 Centrifugal Filter Device 
(molecular weight limit of 100 kDa, Millipore, Billerica, MA, USA). The virus was stored in RV storage buffer 
(10 mM Tris. HCl pH = 7.5, 150 mM NaCl, 10 mM MgCl2·6 H2O, 5% sucrose) at −80 °C. The infectious titer of 
the virus in was determined by plaque assay on HER911 cells and the number of genome copies was determined 
by measuring the optical density of the sample at 260 nm on the Nanodrop ND-1000 spectrophotometer with 
conversion factor 2.1E12. The ratio between the RV particles per ml (vp per ml) and the infectious RV virions in 
PFU per ml ranged from 150:1 to 600:1.
Baculovirus. The recombinant baculovirus AcMNPV expressing JAM-A (BVJAM) was constructed by incorpo-
ration of the human JAM-A gene in the pBlueBac4.5/V5-His vector (Thermo Fisher Scientific, Waltham, MA, 
USA) under control of the polyhedrin promoter. First, the JAM-A cDNA was isolated from the pcDNA-HA-JAM 
plasmid (described before in26) by overlap extension-polymerase chain reaction (PCR) with oligonucleo-
tides FW-haJAM-NheI (GTTGCTAGCCACCATGGGGACAAAGGCGCAAGTC) and RV-haJAM-AgeI 
(GTTACCGGTTACACCAGGAATGACGAGGTCTGTTTGA) and ligated into the pCR-Blunt II-Topo vector 
(Thermo Fisher Scientific) resulting in vector pCR-BluntII-Topo-HA-JAM-A. Plasmids pBlueBac4.5/V5-His 
and pCR-BluntII-Topo-HA-JAM-A were treated with restriction enzymes BshTI and NheI and ligated. This 
resulted in pBlueBac-HA-JAM-A. Sf9 insect cells were co-transfected with the linearized AcMNPV genome of 
the Bac-N-Blue™ Transfection Kit and the pBlueBac-HA-JAM-A transfer vector according to the manufacturer’s 
protocol. The resulting baculoviruses were plaque purified on Sf9 cells and the blue plaques of the recombinant 
baculovirus BVJAM were detected by X-gal staining. Expression of the JAM-A protein on the selected BVJAM clone 
was examined by western blot analysis on the lysate of BVJAM infected Sf9 cells using a monoclonal anti-HA anti-
body (Clone HA-7, H9658, Sigma Aldrich, dilution 1:10,000).
The recombinant baculovirus expressing GFP under the CMV promoter (BV-GFP) was kindly provided by 
Prof. Monique van Oers (Wageningen University, Wageningen, The Netherlands). BVJAM and BV-GFP propa-
gation was performed by infection of Sf9 cells at a MOI of 1 to 3 with a low-passage seed stock. Supernatants 
were harvested 72 h post-infection, cleared from cell debris by centrifugation at 900 × g and 4 °C for 10 min and 
further cleared by ultracentrifugation through a 20% sucrose cushion at 134,000 × g for 1 h at 4 °C. The pellet 
containing the virus was resuspended in sterile phosphate-buffered saline (PBS) by gentle shaking overnight at 
4 °C, before being further purified by ultracentrifugation in a pseudo-linear sucrose-D2O gradient. The gradients 
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were generated from a 50% sucrose solution made in D2O buffered to pH = 7.2 (solution 1) with NaOH and a 30% 
sucrose solution made in 10 mM Tris-HCl pH = 7.2, 150 mM NaCl, 5.7 mM Na2-EDTA (solution 2). The gradi-
ents (10 ml total volume) created by gentle stacking of layers, starting with 1 ml of solution 1 at the bottom, fol-
lowed by 1 ml of a mixture of 90% solution 1 and 10% solution 2, followed by 1 ml of a mixture of 80% solution 1 
and 20% solution 2 etc., ending with 1 ml of solution 2 as last fraction. The virus suspension (maximum of 300 µl) 
was applied on top and gradients were centrifuged for 18 h at 141,000 × g in a Beckman SW28 rotor. Fractions 
of 0.5 ml were collected from the top and the infectious BV titer of each fraction was determined by plaque assay 
on Sf9 cells. The four to five -fractions that contained the highest concentration of infectious BV were pooled and 
centrifuged at 141,000 × g for 1 h at 4 °C. Supernatant was discarded and the pellet was resuspended in PBS by 
gentle shaking overnight at 4 °C. The infectious titer was determined by plaque assay on Sf9 cells and the number 
of genome copies was determined by measuring the optical density of the sample at 260 nm on the Nanodrop 
ND-1000 spectrophotometer. The BV vp to PFU ratio per ml ranged from 100:1 to 300:1.
Establishing the BVJAM-RV complex. For the generation of BV-RV complexes the virus amounts were 
based on the viral particle titers. In the experiments, RV was diluted to the desired concentration in culture 
medium and BV in PBS. The viruses were mixed in a small volume (maximally 50 µl) and incubated at room tem-
perature (RT) for 15–30 min before dilution in the appropriate amount of culture medium and addition to cells in 
standard cell culture conditions or in spheroid cultures.
Electron microscopy analyses. Virions of BVJAM were subjected to electron microscopy as described 
before22. Briefly, virions of BVJAM were diluted in 20 µl 0.14 M NaCl, 0.05 M Tris-HCl buffer pH = 8.2 (TBS) 
before absorbance onto carbon-coated Formvar membranes on electron microscopy grids. Primary antibody 
monoclonal α-JAM (100 μg per ml, ab17261, Abcam, Cambridge, UK or 200 μg per ml and sc-53623, Santa Cruz 
Biotechnology Inc., Dallas, Texas, USA) was applied onto the grids and incubated for 1 h. The grids were rinsed 
with TBS and post-incubated with 10-nm colloidal gold-tagged goat α-mouse immunoglobulin G (IgG) antibody 
(British Biocell International Ltd., Cardiff, United Kingdom; diluted to 1:50 in TBS) for 30 min at RT. After the 
specimens were being rinsed with TBS, they were negatively stained with 1% uranyl acetate in H2O for 1 min at 
RT, rinsed again with TBS, and examined under a TEM 1400 JEOL electron microscope (EM) equipped with an 
Orius-Gatan digitalized camera (Gatan, Grandchamp, France).
The BVJAM-RV complexes in a 25:1 ratio were allowed to form as described above, diluted in TBS buffer and 
applied to the grids prior to the negative staining with uranyl acetate.
Antibody blockage experiments. To examine the capability of two different α-JAM-A antibodies (100 μg 
per ml, ab17261, Abcam and 200 μg per ml, sc-53623, Santa Cruz Biotechnology Inc.) to recognize JAM-A on 
the cell surface, HER911 and U-118 MG cells were dissociated using trypsin (Gibco | Thermo Fisher Scientific), 
fixed in 4% formaldehyde for 15 min at RT and washed in FACS buffer (0.5% BSA, 2 mM EDTA, 0.09% w/v 
sodium azide in PBS). Cells were incubated with the primary α-JAM-A antibodies ab17261 or sc-53623 1:400 
diluted in FACS buffer for 1 h at RT. Next, cells were washed and exposed to the PE fluorochrome-conjugated 
goat α-mouse antibody (12-4010-87, F(ab’)2 IgG, Thermo Fisher Scientific) for 30 min at RT in the dark, 1:3000 
diluted in FACS buffer. After extensive washing, the cells were resuspended in FACS buffer and assayed on a BD 
LSRII flow cytometer. Per sample 10,000 events were measured. In the subsequent experiment to determine 
the ability of both α-JAM-A antibodies ab17261 or sc-53623 to (partly) block a RV infection, HER911 cells in 
96-well plates were incubated with 15 μl α-JAM-A antibodies ab17261 or sc-53623 or unrelated antibodies of the 
same providers (α-fiber, 4D2, Abcam and α-ERAP1 (sc-100727), α-IRF-3 (sc-9082), α-c-Myc (sc-40) from Santa 
Cruz Biotechnology Inc.) for three h followed by the addition of RV (MOI 3 PFU per cell). Culture medium was 
replaced at one h post-infection and two days post-infection cells and medium were harvested, subjected to three 
cycles of freezing and thawing before the infectious RV titer was determined by plaque assays on HER911 cells.
In the confirmatory experiment the U-118 MG cells in a 24-well plate were counted before the start of the 
experiment. The BVJAM (5000 vp per cell BVJAM in PBS/2%FBS in 20 μl) was incubated for 10 min with 25 μl 
α-JAM-A antibody sc-53623, Santa Cruz Biotechnology Inc.), three unrelated antibodies (α-ERAP1 (sc-100727), 
α-IRF-3 (sc-9082), α-c-Myc (sc-40), Santa Cruz Biotechnology Inc.), or as negative control, 25 μl PBS/2%FBS. 
Next, 2000 vp per cell RV, with a total volume of 20 μl, was added and incubated for 15 min before addition 
of 475 μl cell culture medium. RV only and RV incubated with BV-GFP virus were used as controls. 500 μl of 
this solution was incubated with U-118MG for 24 h followed by a replacement of the culture medium. At 48 h 
post-infection the cells and medium were harvested, three cycles of freezing and thawing were performed and the 
RV titer was determined by plaque assays on HER911 cells.
Flow cytometry analyses of reovirus infected cells. U-118 MG cells, in a 24-well plate, were 
incubated with the BVJAM-RV complex or RV alone for 40 h. Next, cells were dissociated with TrypLe Select 
(Gibco | Thermo Fisher Scientific), fixed in 4% formaldehyde for 15 min at RT and washed in staining buffer 
(1% FBS, 0.09% w/v sodium azide in PBS, pH = 7.5, filtered). Cells were subsequently permeabilized in Perm/
Wash Buffer (BD Biosciences, San Jose, CA, USA) for 15 min at RT and incubated with the primary antibody 
against RV σ3 protein, 1:200 diluted in Perm/Wash Buffer for 1 h at RT. Cells were washed and exposed to the PE 
fluorochrome-conjugated rat α-mouse antibody (IgG2a + b, BD Biosciences) for 30 min at RT in the dark, 1:100 
diluted in Perm/Wash buffer. After extensive washing, the cells were resuspended in FACS buffer (0.5% BSA, 
2 mM EDTA in PBS) and assayed on a BD LSRII flow cytometer. Per sample 10,000 events were measured, only 
for the highest virus concentrations (5000 vp per cell RV and 10,000 vp per cell BVJAM) 2,500 cells per sample were 
measured as the majority of the cells already succumbed to the virus infection (see Results section). Data were 
analysed with FACSDiva software (BD Biosciences).
www.nature.com/scientificreports/
1 2SCieNTifiC REPORTS | 7: 17654  | DOI:10.1038/s41598-017-17709-z
Determination of reovirus yield. U-118 MG cells were counted and infected with the BVJAM-RV complex 
or RV alone in a 96-well plate. The inoculum was removed by replacement of the culture medium after 24 h. 
Culture medium and cells were harvested together 4 days post-infection, subjected to three cycles of freezing and 
thawing and cleared from major cell debris by centrifugation for 10 min at 3000 × g. The RV titer of the superna-
tant was determined by plaque assays on HER911 cells.
Caspase assay. Caspase-3 and -7 activity in monolayer U-118 MG cultures upon virus infection was meas-
ured by Caspase-Glo® 3/7 Assay (Promega, Winsconsin, USA). Cells were infected with the BVJAM-RV complex 
or RV alone. The inoculum was removed and replaced by fresh culture medium after 24 h. Culture medium was 
changed again for fresh medium 4 days post-infection before the caspase-3 and -7 activity was assayed according 
to the manufacturer’s protocol.
Preparation and infection of spheroid cultures. The establishment of spheroid cultures of U-118 MG 
cells was described previously in17. In brief, the cells were collected from semi-confluent monolayers by trypsin 
treatment, counted and resuspended in medium containing 2.4 mg per ml methylcellulose (Sigma Aldrich, 
Saint Louis, Missouri, USA) in the desired concentration (250 or 50 cells per μl). The suspension was added to a 
U-bottom 96-well plate, 100 μl per well, and the cultures (25,000 or 5,000 cells) were incubated at 37 °C overnight 
to allow the formation of a spheroid in each of the wells. Methylcellulose was removed by repeated washing with 
medium and spheroids were incubated with the BVJAM-RV complex or RV alone directly after washing.
Cell viability analyses. Cell viability of monolayer cells or spheroids was assessed at respectively 5 and 6 
days post-infection by replacing the culture medium by fresh medium containing 10% WST-1 reagent (Roche, 
Penzburg, Germany). The cells were re-inserted in the incubator for 1 h (for monolayer cultures) or overnight 
(for spheroid cultures) before the absorbance was measured in a microplate reader (Bio-Rad model 550, Bio-Rad, 
Hercules, CA, USA) at a wavelength of 450 nm. The viability measurements were normalized to the viability of 
uninfected cells.
Immunocytochemistry analyses of spheroid cultures. Immunocytochemistry analysis of spheroids 
has been described previously17. Shortly, spheroid cultures were fixed overnight in 4% formaldehyde at 4 °C, 
dehydrated and stained with 1% eosin in ethanol for 10 min. The excess of eosin was removed by washing with 
100% ethanol and the spheroids were incubated in xylene two times 15 min before they were embedded in paraf-
fin. Slices of 6 μm were sectioned from the paraffin blocks on a microtome (Leica RM 2165, Nussloch, Germany), 
transferred to Superfrost Plus slides (Thermo Fisher Scientific) and allowed to dry. The sections were deparaffin-
ised, rehydrated and antigens were retrieved by heating the slides in 10 mM sodium citrate buffer (0.19 g citric 
acid monohydrate and 1.2 g tri-sodium citrate dihydrate in 500 ml H2O) by maintaining the temperature just 
below the boiling point for 6 min. After cooling, slides were washed twice in water, incubated in 0.3% H2O2 for 
10 min and briefly rinsed in water and PBS afterwards. Samples were exposed to a blocking solution (10% goat 
serum in PBS) for 1 h at RT before incubation with an antibody 4F2 directed against the reovirus σ3 protein 
diluted 1:200 in blocking solution for 3 h at RT (monoclonal antibody 4F2 was obtained from the Developmental 
Studies Hybridoma Bank, maintained by The University of Iowa, Department of Biology, Iowa City, IA 52242). 
Next, slides were rinsed in PBS and incubated with the polyclonal goat α-mouse antibody conjugated with horse-
radish peroxidase (HRP) (P0447, Dako, Glostrup, Denmark), 1:50 in blocking solution, for 30 min at RT. The 
slides were washed thoroughly and the cells were stained with a filtered 3,3-diaminobenzidine (DAB) solution 
(10 mg DAB dissolved in 10 ml PBS and mixed with 10 ml H2O and 10 μl 30% H2O2) under the microscope. 
Slides were immersed in water after appearance of the brown colour. After dehydration, the samples were briefly 
immersed in xylene and mounted in Pertex (Pertex Mounting Medium, Leica Biosystems, Wetzlar, Germany).
Measuring diameter and un-infected area of spheroids. Measurements on the sectioned spheroids 
were performed using an Olympus CK40 microscope (Olympus Corporation, Shinjuku, Tokyo, Japan), an 
Olympus Camedia Digital Camera C-3030 and Olympus software; Olympus DP-soft. To determine the middle 
of each spheroid, the diameter of the spheroid sections on each slide was measured in two directions, 90 degrees 
opposite, and averaged. This value was incorporated into a chart and by addition of a trend line the section with 
the largest diameter, representing the middle of the spheroid, became apparent. The non-infected area was meas-
ured from 3-5 middle sections of the same spheroids at six days post-infection and averaged.
Statistical analysis. The statistical significance of key data was assessed with GraphPad Prism V7.02. The 
Shapiro-Wilk normality test was used to confirm that the data follow a Gaussian distribution. Thereafter a T-test 
was performed, unpaired, two-tailed. P-values below 0.05 were considered significant.
Data availability. The authors declare that the data supporting the findings of this study are available from 
the authors upon reasonable request.
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